Kornimate/medical-research-clean huggingface dataset:
the evaluation of recombinant lh supplementation in patients with suboptimal response to recombinant fsh undergoing icsi

Conditions: Infertility

Summary: the investigators aimed to evaluate patients who had in-vitro fertilization treatment and who had coh (controlled ovarian hyperstimulation) cycles applying long protocol with gnrh (gonadotropin-releasing hormone) analogue with suboptimal response to the rfsh. the investigators evaluated and compared the addition of rlh, increasing the dose of rfsh and the control groups regarding the results of ivf in these patients.

1. aim -we aimed to evaluate patients who had in-vitro fertilization treatment and who had coh (controlled ovarian hyperstimulation) cycles applying long protocol with gnrh (gonadotropin-releasing hormone) analogue with suboptimal response to the rfsh. we evaluated and compared the addition of rlh, increasing the dose of rfsh and the control groups regarding the results of ivf in these patients. 2. material and methods -between 01.01.2009-30.04.2011, 137 patients presented with infertility to the unit of assisted reproduction techniques- of the department of obstetrics and gynecology- meram medical faculty- selcuk university and were planned for icsi-et (intracytoplasmic sperm injection-embryo transfer) with normal ovarian function, who had long protocol of gnrh analogue and coh (controlled ovarian hyperstimulation) with rfsh were included in the study. 52 patients were considered responsive to stimulation and composed the normal control group (group 1). on the 7th day of stimulation transvaginal ultrasonography was carried out. patients who had at least 6 follicles about 6-10mm but had no follicle above 10mm and e2 (oestradiol) level of \<250 pg / ml were considered to have suboptimal response to stimulation and were divided into two groups. for group 2 (n = 50), 75iu / l rlh was added to the treatment, for group 3 (n = 35), 75iu / l of rfsh was added to the treatment. ivf results were compared between the groups.

Eligibility criteria:
inclusion criteria: * patients aged 23-39 * body mass index between 18 and 30 kg/m2 * baseline fsh ≤12 iu/l, e2 ≤ 80 pg/ml * the presence of both ovaries and uterine cavity capable of sustaining a pregnancy * who had regular menstrual cycles (21-35 days) confirmed absence of pregnancy and sufficient number of antral follicles on the transvaginal us examination on the 3rd day of menstruation * who were having their first or second ivf trial. exclusion criteria: * grade iii-iv endometriosis * clinically significant condition preventing them from undergoing gonadotrophin treatment * more than two previous assisted cycles * who had a single ovary * unexplained gynaecological bleeding * polycystic ovary or an ovarian cyst of unknown aetiology * previously diagnosed with a space occupying lesion like submucous myoma , polyps, septum, synechia in the uterine cavity * have a chromosomal anomaly.

Keywords: icsi suboptimal ovarian response rlh
improving sleep and quality of life in adults with hiv disease

Conditions: Insomnia

Summary: the purpose of this study is to see if yoga or music therapy can improve the sleep of adults with hiv.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * hiv seropositive * current sleep disturbance * able to speak, read, and write in english * a phone number to maintain contact with research team * willing to provide copy of most recent cd4 and viral load values * willing to wear actigraph for 1 week per month for 3 months * willing to participate in group intervention sessions 3 times per week for 8 weeks exclusion criteria: * pregnancy * psychiatric diagnosis, such as schizophrenia, dementia, bipolar disorder (depression not excluded) * sleep disorder diagnosis, such as apnea or narcolepsy (insomnia not excluded) * current yoga practice

Keywords: hiv sleep insomnia yoga music
bioequivalence study of torrent pharmaceuticals ltd.'s rosuvastatin calcium tablets under fed conditions

Conditions: Healthy Subjects

Summary: subjects to compare the single dose bioavailability of torrent's rosuvastatin calcium tablets 40 mg and crestor® 40 mg tablets of astrazeneca pharmaceuticals lp, usa. dosing periods of studies were separated by a washout period of 7 days.

an open label, randomized, 2-period, 2- treatment, 2-sequence, crossover, single-dose bioequivalence study of rosuvastatin calcium tablets containing rosuvastatin calcium 40 mg ( test formulation, torrent pharmaceutical ltd., india) versus crestor® 40 mg tablets containing rosuvastatin calcium 40 mg (reference , astrazeneca pharmaceuticals lp, usa) in healthy human volunteers under fed condition.

Eligibility criteria:
inclusion criteria: * sex: male * age: 18-45 years * volunteer with bmi of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight. * healthy and willing to participate in the study. * volunteer willing to adhere to the protocol requirements and to provide written informed consent. * non-smokers or smoker who smokes less than 10 cigarettes per day. exclusion criteria: * the volunteers were excluded from the study based on the following criteria: * clinically relevant abnormalities in the results of the laboratory screening evaluation. * clinically significant abnormal ecg or chest x-ray. * systolic blood pressure less than 100 mm hg or more than 140 mm hg and diastolic blood pressure less than 60 mm hg or more than 90 mm hg. * pulse rate less than 50/minute or more than 100/minute. oral temperature less than 95°p or more than 98.6°p. * respiratory rate less than 12/minute or more than 20/minute * history of allergy to the test drug or any drug chemically similar to the drug under investigation. * history of alcohol or drug abuse * positive breath alcohol test * recent history of kidney or liver dysfunction. * history of consumption of prescribed medication since last 14 days or otc medication since last 07 days before beginning of the study. * volunteers suffering from any chronic illness such as arthritis, asthma etc. * history of heart failure. * hiv, hcv, hbsag positive volunteers. * opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, cocaine positive volunteers based on urine test. * volunteers suffering from any psychiatric (acute or chronic) illness requiring medications. * administration of any study drug in the period 0 to 3 months before entry to the study. * history of significant blood loss due to any reason, including blood donation in the past 3 months. * history of pre-existing bleeding disorder. * existence of any surgical or medical condition, which, in the judgment of the chief investigator and/or clinical investigator/physician, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers. * inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.
telerehabilitation for patients with chronic respiratory failure.

Conditions: Chronic Respiratory Disease; Exercise

Summary: it is widely described in the literature that exercise training improves patients' exercise tolerance, quality of life, symptoms, anxiety and depression, regardless of the location. despite overwhelming evidence of the benefits of exercise training, only a very small percentage of eligible people have ever completed a program. alternative modes of exercise training are needed to improve equity of access for patients with chronic respiratory disease. so telerehabilitation, using information and communication technologies to provide distance exercise training services, may be an answer.


Eligibility criteria:
inclusion criteria: * chronic respiratory disease patients * patients with dyspnea or exercise intolerance. * stable patients at home. * patients who can use a computer (after explanations) and have adequate hearing and vision. * collection of the patient's non-objection exclusion criteria: * life expectancy \<3 months. * absolute contraindication to performing physical activity * hospitalization for exacerbation in the two months prior to inclusion.
treatment of tendon injury using allogenic adipose-derived mesenchymal stem cells (rotator cuff tear)

Conditions: Rotator Cuff Tear

Summary: main purpose of this study is to evaluate efficacy of allogenic adipose-derived mesenchymal stem cells in treatment of tendon injury. allo-asc will be administrated to the patients with supraspinatus partial thickness tear by ultrasonographic guided injection.

injection volume depends on the size of lesion on ultrasound examination. and all injection will be done under ultrasound guidance. double blind randomized placebo controlled study will be done with following 3 groups. each group will have 8 people, so, the total patients will be 24 people. 1. stem cell treatment group : stem cell 0.5cc (total: 10 million cells) + fibrin glue 0.5cc + range of motion exercise 2. active control (fibrin glue) group : normal saline 0.5cc + fibrin glue 0.5cc + range of motion exercise 3. control (normal saline) group : normal saline 0.5cc + normal saline 0.5cc + range of motion exercise the investigators will compare the efficacy difference with vas(visual analog scale, primary outcome), ases(american shoulder and elbow surgeons) score, ucla(university of california, los angles) shoulder score, dash(the disabilities of the arm, shoulder and hand) score and change of tear size compared to the baseline image assessed by mri. these measurement will be done at 6 and 12 weeks after injections and long-term follow-up will be also planned to 6 months, 12months and 24 months except for the evaluation of the tear size which will be done at baseline, 3 months and 24 months after the intervention.

Eligibility criteria:
inclusion criteria: * clinically diagnosed as rotator cuff tear (supraspinatus partial thickness tear) * recurrent pain in spite of conservative treatment such as physical therapy, medication, steroid injection * symptom duration is over 3 months * supraspinatus partial thickness tear proven ultrasonography and magnetic resonance image(mri) * patient that can understand the clinical trials exclusion criteria: * patient that underwent other injection treatment within 6 weeks * some associated diseases (adhesive capsulitis, full thickness supraspinatus tear,. arthritis of related joint to the target lesion, muscle weakness or atrophy, innervated by suprascapular nerve, paralysis of related joint to target lesion, proximal humeral fracture, infectious disease, bilateral rotator cuff tear, generalized pain syndrome, radiculopathy, rheumatoid arthritis, impaired sensibility, dementia, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue and contraindication to mri * patient that enrolled other clinical trials within 30 days * history of drug/alcohol addiction, habitual smoker, operation, allergic reaction to fibrin glue, local anesthetics and bovine-derived proteins and severe medical disease.

Keywords: adipose derived mesenchymal stem cell allogeneic stem cell rotator cuff tear
behavioral intervention for insomnia in older adults

Conditions: Sleep Initiation and Maintenance Disorders

Summary: the purpose of the study was to evaluate and compare the efficacy of single interventions (stimulus control instructions, sleep restriction therapy) and multi-component intervention (stimulus control instructions and sleep restriction therapy) for chronic insomnia in community dwelling older adults. the subjects were randomly assigned to one of four conditions: stimulus control instructions, sleep restriction therapy, multi-component treatment (stimulus control instructions and sleep restriction therapy), or measurement control.


Eligibility criteria:
inclusion criteria: * 55 years or older * sleep onset or maintenance insomnia of 45 minutes or more per night for at least 3 nights per week as ascertained through 14 days of sleep diaries * insomnia duration of at least 6 months * impaired daytime functioning as a consequence of insomnia exclusion criteria: * psychopathology evidenced by the brief symptom inventory global severity index t score \>60 * cognitive impairment as ascertained by the mini-mental state exam score \< 27 * current psychotherapy or medical treatment for major depression or other psychopathology * current and regular use of over-the-counter medication or prescription medication for sleep (verified through urinalysis), or any medication affecting sleep * major physical or mental illness directly related to the onset and course of insomnia * substance abuse problem ascertained per interview * suspicion of sleep apnea as determined by an epworth sleepiness scale score of 11 or greater, a respiratory disturbance index of \> 15 as established through in-home overnight use of the edentec model 3711 digital recorder, and interview with a significant other, if available * restless leg syndrome, periodic limb movement disorder, or circadian rhythm sleep disorders as determined through the participant interview and an interview with a significant other, if available.

Keywords: sleep initiation and maintenance disorders behavior therapy
children and adolescents with leukemia, brain tumors, and sarcomas

Conditions: Leukemia; Brain Tumor; Sarcoma; Childhood Cancer; Cancer; Adolescent Cancer

Summary: aim of this study is to investigate the influence of social factors on participation and activity among children and adolescents aged 10-18 years with leukemia, brain tumors, and sarcomas. furthermore personal and treatment-related factors and their impact on participation will be explored

background: about 2000 children and adolescents under the age of 18 develop cancer each year in germany. because of more differentiated diagnostics and standardized treatment protocols, a high survival rate can be reached for many types of the disease. nevertheless, patients face a number of long-term effects related to the treatment. as a result, physical and psychological consequences have increasingly become the focus of research in recent years. social dimensions of health have rarely been investigated in pediatric oncology so far. yet, there are no robust results that allow an estimation of whether and to what extent the disease and treatment impair the participation of children and adolescents and which factors mediate this effect. social participation is of great importance especially because interactions with peers and experiences in different areas of life are essential for the development of children and adolescents. methods: data are collected in a longitudinal, prospective, observational multicenter study. for this purpose, all patients and their parents who are being treated for cancer in one of the participating clinics throughout germany will be interviewed within the first month after diagnosis (t1), after completion of intensive treatment (t2) and half a year after the end of intensive treatment (t3) using standardized questionnaires. analysis will be done by descriptive and multivariate methods. recruitment: patients will be consecutively recruited in one of the participating clinics throughout germany.

Eligibility criteria:
inclusion criteria: * newly diagnosed with confirmed leukemia, brain tumor or sarcoma * age 10-18 years * written informed consent of the patient and of one of the parents if they are under the age of 18 exclusion criteria: * having a relapse or secondary tumor * insufficient command of german * profound cognitive and physical impairments

Keywords: social inequalities social dimensions of health brain tumors leukemia sarcomas childhood cancer children and adolescents with cancer
double-blind, multicenter, study to evaluate the efficacy of plx pad for the treatment of covid-19

Conditions: COVID; ARDS

Summary: this clinical trial will examine if a new treatment of mesenchymal-like adherent stromal cells (called plx-pad) can help patients intubated and mechanically ventilated due to covid-19 to recover more quickly with less complications.


Eligibility criteria:
key inclusion criteria: * willing and able to provide written informed consent, or with a legal representative who can provide informed consent. * male or non-pregnant female adult 40-80 years of age at time of enrollment. * laboratory-confirmed sars-cov-2 infection as determined by pcr, in any specimen up to 21 days prior to randomization. * meets definition of ards according to berlin criteria. key exclusion criteria: * body weight under 55 kg (121 lbs) * serum creatinine level of over 1.5 mg/dl at time of randomization. * total bilirubin ≥2 mg/dl at time of randomization. * known allergy to any of the following: dimethyl sulfoxide (dmso), human serum albumin, bovine serum albumin. * stroke or acute myocardial infarction/unstable angina within 3 months prior to randomization. * chronic obstructive pulmonary disease gold stage above ii.
mesh fixation intep inguinal hernia repair

Conditions: Inguinal Hernia

Summary: mesh fixation is used to prevent recurrence in tep to the potential cost of pain. the aim was to evaluate the impact of permanent fixation (pf) versus non-permanent fixation (n-pf) of mesh in tep repair for a primary inguinal hernia regarding chronic pain. a cohort of patients were studied for pain interfering with sexual activety. the hyopthesis is that fixation causes pain.

mesh fixation is used to prevent recurrence in tep to the potential cost of pain. the aim was to evaluate the impact of permanent fixation (pf) versus non-permanent fixation (n-pf) of mesh in tep repair for a primary inguinal hernia regarding chronic pain. men between 30 and 75 years, consecutively registered in swedish hernia register (shr) for a tep repair between 2005 and 2009 were included. a questionnaire was sent in 2010 including a general questionnaire, sf-36 and inguinal pain questionnaire (ipq). primary endpoint was question two in ipq, "worst pain you felt in the operated groin during this past week". pain was defined as "pain present that could not be ignored". in adition a specific questionnair developed by the research group on pain and problems during sexual activiety were sent to patients between 30-60 years of age. the register was checked for long term recurrent operations.

Eligibility criteria:
inclusion criteria: * male between 30-75 years. * primary inguinal hernia exclusion criteria: * emergency operation * operated for recurrence * deaths

Keywords: inguinal hernia tep chronic pain male sex mesh fixation quality of life national register
multimodal gait training with and without rhythmic auditory stimulation in chronic stroke patients

Conditions: Chronic Stroke Patients

Summary: the primary goal of this randomized clinical trial is to investigate the efficacy of multimodal gait training, with and without rhythmic auditory stimulation, in improving gait, coordination and reducing fall risk in individuals with chronic stroke this clinical trial features two distinct groups 42 participants were randomly divided into two groups of 21. group a will receive multimodal gait training along with rhythmic auditory stimulation while group b will receive only multimodal gait training participants will: * take 12 sessions of the mmgt program over six weeks * with each session lasting 45 minutes, including 10-minute rest breaks.


Eligibility criteria:
inclusion criteria: * participants of age between 45 and 70 year * participants of both genders were included. * participants who were able to walk independently indoors without walking aid * participants were included if they had lower limb motor impairment (fugl-meyer assessment lower extremity (fmle) score less than score less than 34 * participants with stroke lasting longer than six months * participants with mini-mental status examination score 24 or more than 24 * participants with the capability to keep in sitting position for 30 minutes * participants with the history of fall in the past year * participants with no visual or auditory impairments that would interfere with the training exclusion criteria: * participants with respiratory problems. * participants with any orthopedic condition. * participants with aphasia that impeded communication. * participants with have severe cardiac disease. * participants with resistant hypertension despite use of medication (average systolic blood pressure ≥ 140 mmhg or average diastolic blood pressure ≥ 90 mmhg measured over 7 days) * participants with presence of non-healing ulcers in the lower limbs, and osteoporosis

Keywords: chronic stroke gate training multimodal rhythmic auditory stimulation
efficacy of gabapentin vs. placebo for adjuvant pain control following acute rib fractures

Conditions: Acute Pain

Summary: a multi-center, randomized controlled trial of the efficacy of gabapentin vs. placebo for adjutant pain control following acute rib fractures.

traumatic rib fractures are a tremendous source of pain which can limit respiratory function and overall recovery. numerous multimodal pain management strategies have been employed with varying success; however, narcotics remain the mainstay of treatment. beyond the acute side effects of narcotics, including altered mental status, depression of respiratory drive, and constipation, there is a substantial risk of long term dependency. recently, loco-regional blockade and non-narcotic adjuncts have received increasing support within the literature. gabapentin has been used extensively as a non-narcotic adjunct to analgesia regimens in the acute and chronic settings, however its ability to better control pain secondary to traumatic rib fractures has never been studied . the primary aim is to assess the efficacy of gabapentin as an analgesic after rib fractures. secondary aims are to assess the effect on pulmonary function and other known complications following rib fractures. the hypothesis is gabapentin will improve pain control as measured by lower pain scores and lower narcotic needs. the investigators plan to test this hypothesis by recruiting trauma patients with rib fractures, and randomly assign them to gabapentin versus a placebo.

Eligibility criteria:
inclusion criteria: * \> 1 rib fractures * requiring hospital admission * enrolled within 24 hours of injury exclusion criteria: * pregnancy * intubation * age \ 65 * inability to tolerate po medication * patient refusal * inability to obtain consent from patient or surrogate * renal or hepatic impairment * allergy or hypersensitivity to gabapentin or any component of the formulation